Moderna: intismeran with pembrolizumab improved outcomes in resected melanoma
According to TradingView, the INTerpath-001 trial showed better RFS and DMFS for intismeran plus pembrolizumab than for pembrolizumab alone in melanoma patients.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, the INTerpath-001 trial found that combining intismeran with pembrolizumab improved RFS and DMFS compared with pembrolizumab alone in patients with resected stage IIB–IV melanoma.
The combination produced a similar rate of serious adverse events. Follow-up for overall survival is still ongoing, so final data on that measure are not yet available.
why it matters
For Moderna, this is an important clinical signal in oncology, an area the company is developing alongside its vaccine programs. Investors will watch the overall survival data, since that measure will determine how much weight this result carries for the drug's future commercial prospects.
market impact
Moderna (MRNA): positive trial data for the cancer drug supports interest in the company
tags
instruments
sources
- MRNA: Intismeran plus pembrolizumab improved RFS and DMFS in resected melanoma — TradingView, 24 October 2026 at 21:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗